Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Limertinib Plus Carboplatin and Etoposide in EGFR-mutant NSCLC With SCLC Transformation
NCT07001995Phase 2Not yet recruiting
- Sponsor
- Hunan Cancer Hospital
- Start
- May 2026
- Primary completion
- Dec 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of limertinib in non-small cell lung cancer (NSCLC), sponsored by Hunan Cancer Hospital. Planned start May 2026; status: not yet recruiting.
02
Drugs
limertinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT07001995.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07001995.